Method of treating a bladder cancer using a chimeric egf-targeted bacterial toxin
AssigneePurdue Research Foundation
InventorsRuben Claudio Aguilar, Timothy L. Ratliff
Life of this patent
Estimating the term…
Abstract
Provided is a method of treating a bladder cancer in an animal or human comprising: administering to an animal or human patient a therapeutic composition comprising a first fusion protein capable of specifically binding to an epidermal growth factor receptor (EGFR) on the surface of a cancer cell and comprising an epidermal growth factor (EGF) polypeptide conjugated to a bacterial toxin polypeptide and a second fusion protein comprising an anthrax Lethal Factor N-terminus (LFN) conjugated to a Diptheria Toxin A (DTA) catalytic domain.
Claims10
A method of delivering a therapeutic agent to a bladder cancer cell in an animal or human patient, said method comprising:
- administering to an animal or human patient in need thereof a therapeutic composition specifically targeting a cancer cell in the bladder of said patient comprising:
- a first fusion protein capable of specifically binding to an epidermal growth factor receptor (EGFR) on the surface of a cancer cell and comprising an epidermal growth factor (EGF) polypeptide conjugated to a bacterial toxin polypeptide;
- a second fusion protein comprising an anthrax Lethal Factor N-terminus (LFN) conjugated to a Diptheria Toxin A (DTA) catalytic domain;
- and
- a pharmaceutically acceptable carrier.
A method of treating a bladder cancer in an animal or human patient, said method comprising:
- administering to an animal or human patient in need thereof a therapeutic composition specifically targeting a cancer cell in the bladder of said patient comprising:
- a first fusion protein capable of specifically binding to an epidermal growth factor receptor (EGFR) on the surface of a cancer cell and comprising an epidermal growth factor (EGF) polypeptide conjugated to a bacterial toxin polypeptide;
- a second fusion protein comprising an anthrax Lethal Factor N-terminus (LFN) conjugated to a Diptheria Toxin A (DTA) catalytic domain;
- and
- a pharmaceutically acceptable carrier.
A kit comprising a first container having a first fusion protein capable of specifically binding to an epidermal growth factor receptor (EGFR) on the surface of a cancer cell and comprising an epidermal growth factor (EGF) polypeptide conjugated to a bacterial toxin polypeptide, a second container having a second fusion protein comprising an anthrax Lethal Factor N-terminus (LFN) conjugated to a Diptheria Toxin A (DTA) catalytic domain, and optionally a third container having a pharmaceutically acceptable carrier, and instructions for preparing a therapeutic composition comprising effective amounts of the first and second fusion proteins and the pharmaceutically acceptable carrier, wherein said therapeutic composition is formulated for delivering an effective amount of the therapeutic composition to the lumen of the bladder of a patient in need thereof for modulating the proliferation or viability of cancer cells in said patient.
A therapeutic composition comprising:
- a first fusion protein capable of specifically binding to an epidermal growth factor receptor (EGFR) on the surface of a cancer cell and comprising an epidermal growth factor (EGF) polypeptide conjugated to a bacterial toxin polypeptide;
- a second fusion protein comprising an anthrax Lethal Factor N-terminus (LFN) conjugated to a Diptheria Toxin A (DTA) catalytic domain;
- and
- a pharmaceutically acceptable carrier,
- wherein the therapeutic composition is formulated for delivering an effective amount of the therapeutic composition to the lumen of the bladder of a patient in need thereof for modulating the proliferation or viability of cancer cells in said patient.
Dependencies are inferred from the claim text.